Skip to main content
Premium Trial:

Request an Annual Quote

Italy's Menarini Acquires Cell Array Firm Silicon Biosystems

NEW YORK (GenomeWeb News) – Italian pharmaceutical and diagnostics firm the Menarini Group has acquired Bologna-based Silicon Biosystems for an undisclosed sum, the firms announced today.

Silicon Biosystems has commercialized a microelectronic array-based platform, called DEPArray, that can isolate and manipulate cells, including rare cells such as stem cells and circulating tumor cells, in a suspension matrix.

Lucia Aleotti, chairman of the Menarini Group, said that the acquisition of Silicon Biosystems adds an "innovative high-tech company" to its existing programs in oncology.

As part of the Menarini Group, Silicon Biosystems will continue to operate as a standalone entity, the firms said, but will also have access to the "support and resources needed" to develop its technology and expand into clinical markets.

Founded in 1999, Silicon Biosystems expanded to the US in 2010 when it opened a subsidiary in San Diego. The company has since announced partnerships with Fox Chase Cancer Center, Baylor College of Medicine, and PGXL Technologies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.